Search
AV-COVID-19
go.drugbank.com/drugs/DB15802InvestigationalAs of July 2020, the company is pursuing an adaptive Phase IB-II Randomized Clinical Trial (NCT04386252) to test the vaccine. … The monocytes are then differentiated in vitro into dendritic cells with IL-4 and GM-CSF, incubated with SARS-CoV-2 antigens prior to administration.
Mephenytoin
go.drugbank.com/drugs/DB00532ApprovedWithdrawnMephenytoin and oxazolidinedione derivatives are associated with higher incidences of blood dyscrasias compared to other anticonvulsants. … These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. Mephenytoin is known to target sodium channel protein type 5 subunit alpha.
HPA-23
go.drugbank.com/drugs/DB17739ExperimentalHPA-23 is an investigational antiviral compound.[A259142]
3,5-diiodothyropropionic acid
go.drugbank.com/drugs/DB12629InvestigationalDITPA has been investigated in Congestive Heart Failure.
CoVac-1
go.drugbank.com/drugs/DB16429InvestigationalIt is being investigated in the clinical trial NCT04546841 (Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults (pVAC))[L30428] and aims to induce broad … Sponsored by the University Hospital Tuebingen in Germany, CoVac-1 is a multi-peptide COVID-19 vaccine candidate created from HLA class I and HLA-DR T-cell epitopes of the S-protein[A226588].
Categories: Complex MixturesAlfaxalone
go.drugbank.com/drugs/DB11371ExperimentalVet approvedIt is used in veterinary practice under the trade name Alfaxan, and is licensed for use in both dogs and cats.
QAV-680
go.drugbank.com/drugs/DB11658InvestigationalQAV680 has been used in trials studying the treatment of Asthma, Allergic Rhinitis, and Seasonal Allergic Rhinitis.
Landogrozumab
go.drugbank.com/drugs/DB11862InvestigationalLandogrozumab has been used in trials studying the treatment of Advanced Cancer, Muscular Atrophy, and Pancreatic Cancer.
Rivoceranib
go.drugbank.com/drugs/DB14765InvestigationalRivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of Advanced Pancreatic Cancer).